Valneva to present on its chikungunya vaccine ixchiq®, participate in multiple events at the 24th world vaccine congress in washington d.c.

Saint-herblain (france), march 21, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, ixchiq®, moderate a roundtable on the zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate chikungunya at the 24th world vaccine congress, which will take place between april 1-4, 2024 at the walter e. washington convention center in washington, d.c. the company will have a display in the exhibit area of the congress at booth #433.
VALN Ratings Summary
VALN Quant Ranking